Current and Emerging Immunotherapeutic Strategies in Melanoma

In an interview with Targeted Oncology for World Cancer Day, Manmeet Ahluwalia, MD, MBA, FASCO, explored the key challenges facing community oncology and the strategies needed to close these gaps.

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies are offering hope for more durable remissions and better quality of life.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the FDA with priority review.